Try our Advanced Search for more refined results
Life Sciences - June, 2020
416 articles
- 3 Developments As HHS Officials Paint Dark Pandemic Picture
- Legal Teams Vie To Lead COVID Test Supply Stock Drop Suit
- Medical Parts Co. Says $74M Fight Doesn't Belong In Ga.
- Ex-Indivior CEO Cops To Misdemeanor In Opioid Case
- DOJ Charges Glenmark With Generic Drug Price-Fixing
- Biogen Gets Temporary Halt On Unapproved Mylan MS Drug
- Justices Told Congress Must Craft PTAB Constitutional Fix
- Procopio Boosts IP Practice In Calif. With 7 Arent Fox Attys
- SEC Fines Ex-Biotech CEO For Fertility Drug Misstatements
- Genomic Health Investor Calls Exact Sciences Merger Unfair
- Colorado Gov. Signs Cannabis Social Equity Bill Into Law
- Imerys Ch. 11 Sale Process OK'd Despite Insurer Concerns
- Virus Delays Second Round Of Illinois Marijuana Licenses
- Coronavirus Regulations: A State-By-State Week In Review
- What You Say In Online Mediation May Be Discoverable
- Why FDA's Proposed Food Standard Principles Are Important
- Key Defense Approaches To 'Other Similar Incident' Evidence
- Amputee's Widow Aims To Keep Bayer, Merck On The Hook
- BlackRock Joins Goldfinch Bio's $100M Series B Round
- Trade Groups Face Antitrust Questions In Pandemic Response
- IP Risks To Consider When Joining 'Open COVID Pledge'
- UK Watchdog Skeptical Of Stryker's $4B Wright Medical Deal
- 9th Circ. Won't Revive PetIQ Merger Challenge
- Pfizer Calls For Fees On US Merck Pneumonia Vaccine At Trial
- Pharmacies Urge 6th Circ. To Boot Opioid MDL Judge
- Bayer, Beiersdorf Can't Ditch Or Move Coppertone Claims
- Advocates Unimpressed With Iowa Low-THC Program Tweaks
- AmerisourceBergen CEO Must Testify In Opioid Bellwether
- Justices Told PTAB Appointments Are Not Unconstitutional
- Bayer, GE Must Face Suit Over Woman's Chemical Sickness
- Fortress Drops Ex-Theranos IP Suit To Let Test Co. Fight Virus
- Endo Investors Seek Cert. After Losing Price-Fixing Claims
- House Passes Dems' ACA Booster Bill Despite Veto Threat
- Sens. Add Marijuana Research Expansion To Defense Bill
- Labaton Sucharow To Lead Abiomed Stock-Drop Class Action
- Calif. Delays Pot Licensing Fees Amid Pandemic
- Top 6 Patent Rulings Of 2020: A Midyear Report
- Covington, Freshfields-Led Biotech Co. Nabs $251M Financing
- Mylan Hit With Stock-Drop Suit Over Test Manipulation
- Nursery Tells 11th Circ. Pot License Constitutionally Protected
- Treat Hemp Like Any Other Industry, FinCEN Urges
- FDA Ducks Suit Challenging Stimulant Crackdown
- 9th Circ. Told To Dig Into 'Tribunal' Meaning In Discovery Fight
- Mass. Court Deadline Tolling Will Cause Problems For Years
- 10 Tips For A Successful Remote Arbitration Hearing
- J&J Can't Beat $186M Punitive Award In Talc Asbestos Case
- Pfizer Says HHS Is Blocking Patient Access To Heart Drugs
- J&J Put In A Corner By Court That Slashed $4.7B Talc Verdict
- Dispensary Says Md. Pot Board Discrimination Case Tenable
- 3rd Circ. Urged To Revive Pelvic Mesh Atty Fees Suit
- COVID-19 IP Catch-Up: Mask Sales & Remote Source Codes
- Fresenius Takes Fiery Aim At Akorn's Ch. 11 Plan Disclosures
- Inovio Can't Force Supplier To Share COVID-19 Vaccine Tech
- 5 Tech And Life Sciences Cos. Raise Nearly $1B Total In IPOs
- High Court's SEC Enforcement Ruling Has Tax Consequences
- Surescripts Says Pharmacies' Antitrust Claims Too Indirect
- Talc Maker Can't Interview Ex-Jurors After Virus Mistrial
- Latham-Led Pesticide Group Lands $45M Funding Round
- 7th Circ. Won't Revive Merck Employee Bias Suit
- Insys Founder Says 4th Circ. Ruling Aids New Trial Bid
- 5th Circ. Snuffs Challenge To FDA Regulation Of E-Cigs
- Celgene Fights Investors' Class Cert. Bid In Stock-Drop Suit
- To Achieve Diversity, Law Firms Must Reinvent Hiring Process
- Taxation With Representation: Simpson, Cadwalader, Latham
- A New Antitrust Approach After Humira 'Patent Thicket' Ruling
- UK Litigation Roundup: Here's What You Missed In London
- 'Compound King' Gets 10 Years For $22M Health Care Fraud
- Cities May Seek Statewide UCL Relief, Calif. Justices Say
- Chief SDNY Judge Says Drug Cos. Ready For Remote IP Trial
- Robbins Geller Will Lead Investor Suit Against Mallinckrodt
- 5th Circ. Won't Revive Suit Against Allergy Advocacy Group
- AbbVie, FTC Tussle Over High Court's View On Disgorgement
- GNC Can Tap Into Ch. 11 Funds Despite Creditor Opposition
- Cannabis Cos. Settle Supply Agreement Dispute For $21M
- Investors Fight CBD Co.'s Bid To Ax Suit Over Clinical Trial
- Cybersecurity Steps For Law Firms Amid Heightened Risks
- 4 Tips For Defending Consolidated Cases
- Army Wants To Reconsider Disputed Medicine Dispenser Deal
- Hong Kong Cancer Drug Co. Snags $100M Equity Investment
- Bayer Ducks Suit Over Birth Control Device Defect Claims
- Congress Could Still Pass Cannabis Legislation In 2020
- Consumer Device Data May Pose Problems In Med Mal Suits
- Cancer Biotech Lands $110M In Financing, Refiles For IPO
- Novartis Units Pay $346M Over US Bribery Claims
- Bayer Offers $400M To Settle Dicamba Suits With Farmers
- J&J Surgical Rip-Offs Lead To Seizure, FDA Criminal Probe
- Full Fed. Circ. Skips Biogen Fight Over MS Drug Patent
- Acuity Must Defend Pharma Co. In Opioid Liability Suits
- Mich. Pot Industry Expects A Boost From Regulatory Overhaul
- Prevagen Maker Inks Deal To Settle Half-Dozen False Ad Suits
- Ex-Marine Aims To Kill 3M Suit Alleging Massive N95 Scam
- Regeneron Paid Kickbacks To Boost Eye Drug, Feds Say
- State Farm Faces Suit By Chiropractor Over 'Virus Exclusion'
- An Inside Look At DOJ Fight Against COVID-19 Price-Gouging
- The Research Compliance Landscape Is Evolving Quickly
- A Strategy To Address Uncertainty In Life Sciences Contracts
- UK Justices' Regeneron Ruling Puts Hurdle In Biotech IP Race
- Class Cert. Denied In Suit Over Faulty Embryo Storage Tank
- It's Time For Law Firms To Support Work-From-Home Culture
- Republicans Keep Confirming Unqualified Judicial Nominees
- With $10B Deal, Bayer Aims To Put Roundup Battles Behind It
- How Trump Forever Changed Judicial Nominations
- GNC Falls Into Ch. 11 Due To COVID-19 With $1B-Plus Debt
- Top UK Court Invalidates Regeneron's Lab Mice Patents
- Court Trims Challenge To Ill. Cannabis Licensing Scheme
- Top Health Officials Contradict Trump On Pandemic Response
- Bayer Foe Blocked From Serving Docs Via Email Amid Virus
- Agencies Hit With FOIA Suit Over Request For DNA Docs
- Walmart Accused Of Misrepresenting Toddler Formula
- Gilead To Buy 49.9% Stake In Latham-Led Drug Co. For $275M
- Philips Says Chinese Rivals Can't Skirt Ill. Trade Secret Suit
- Obviousness Doomed Narcan Patents After NJ Bench Trial
- Omnicell Says DOD Bid Process Altered To Kill Competition
- Shareholder Suit Over GTx And Oncternal Merger Tossed
- Valeant Tells Full Fed. Circ. Relistor Patent Ruling Is 'Alarming'
- Medical Services Co. Seeks Arbitration In Trade Secret Fight
- Chicago Says Drug Cos. Shouldn't Exit Opioid Bellwether Suit
- High Court Missed Chance To Define SEC Enforcement Limits
- 9th Circ. Won't Revive Cannabis Patient's Eviction Challenge
- Tips For Crafting The Perfect Law Firm Alert
- Coronavirus Regulations: A State-By-State Week In Review
- Pandemic May Push 1st Zofran MDL Bellwether To 2021
- Purdue Gets OK For $6.5M Investment In Overdose Drug
- Mo. Appeals Court Slashes $4.7B Talc Verdict Against J&J
- Purdue Wants Sackler Claims To Stay Blocked By Ch. 11
- Biopharma Patentees Must Navigate Inherent Obviousness
- 7th Circ. Won't Revive 'Perplexing' AbbVie Stock Drop Suit
- Alere Tells PTAB To Reconsider New Record On SAS Remand
- FDA Says To Avoid 9 Potentially Harmful Hand Sanitizers
- Atty, Co. Must Pay Sanctions After Tossed Takeda Unit Suit
- Travelers Drops Suit Claiming Qatar Airways Damaged Cargo
- Cook Medical Wants Fraud Claims Tossed From MDL
- CORRECTED: Monsanto Blocks Calif. Glyphosate Cancer Warning Label
- Mo. Medical Pot Regulators Probe Fraudulent Patient Licenses
- 4 Cos. Join Busy IPO Pipeline With Launches Totaling $598M
- Novartis Seeks To Block Imports Of German-Made Eye Shots
- Judging A Book: Elrod Reviews 'Shortlisted'
- Mandatory State Bars Likely To Remain Intact, For Now
- Genetics Co. Inks $1.4B Deal With Cooley-Led Cancer Tech Biz
- Justices Skip Retroactive IPRs, Doctrine Of Equivalents
- Investor Says Endo Lied About Role In NY Opioid Crisis
- Shareholders Seek Class Cert. In Teva Price-Fixing Suit
- Roundup Atty, Partner Cop To $200M Corporate Extortion Plot
- 4th Circ. Orders New Trial For W.Va. Doctor In Opioid Case
- 4 Life Sciences Companies Price IPOs Totaling $854M
- Cigar Groups Ask Full 4th Circ. To Allow E-Cig Rule Challenge
- FTC Sends Another Round Of COVID-19 Warnings
- COVID-19 IP Catch-Up: Trials Get Delayed, Moved To Video
- If We Used Current Patent-Eligibility Tests On Vintage Patents
- When Is The Hypothetical Negotiation For Patent Damages?
- 11 Keys To Success At Remote Mediation
- Hot Air Balloons Face Pesticide Risk, Calif. Farm Tells EPA
- Diagnostics Co. Sued After COVID-19 Test Revoked By FDA
- Essure Negligence Suit Shouldn't Be In Pa. Court, Bayer Says
- Wright Medical, MicroPort Don't Want Implant Suits In MDL
- Vaccine Co. Must Face Claim It Illegally Refused Job Applicant
- Robbins Geller Will Lead Proposed Inovio Investor Class
- Pharma Co. Must Mediate EpiPen Pricing Claims With Mylan
- Perrigo Inks $195M Sale Of UK Generics Manufacturer
- UK Litigation Roundup: Here's What You Missed In London
- 3 Trends Underlying The Boom In Blank-Check IPOs
- Fed. Circ. Grants Arthrex Remand In Ex Parte Reexam
- Mylan Gets Biogen MS Drug Patent Invalidated In W.Va. Court
- Smart-Pill Maker Plans Ch.11 Sale Of 'Science Fiction'-Like IP
- EPA Lists New Substance As Hazardous Under Clean Air Act
- 3M Settles Another Price-Gouging TM Case Over N95 Masks
- DOJ Wants To Keep Generic-Drug Exec's Case In Pa.
- FDA Opens Useful Dialogue On Orange Book Patent Listings
- Pa. Justices Scrap Ban On Medical Pot For Probationers
- Pandemic Could Bring Student Exodus From Legal Profession
- Walmart Investors Want Docs To Probe Role In Opioid Crisis
- Chinese Co. Charged With Selling Defective Respirator Masks
- Deals Rumor Mill: Bombardier, Thyssenkrupp, CureVac
- Justices Told Suboxone Ruling Lets PTAB 'Do As It Pleases'
- Maine Cannabis Residence Suits Raise Thorny Federal Issues
- Mylan Faces Fight To Bar Generic Sleep Aid As Launch Nears
- Edwards Can't Fully Launch Heart Device Amid Patent Appeal
- Virus Fears Mean Serenity, Ferring Will Have Remote IP Trial
- Shire Wants Jury Trial Over Validity Of Its Genetic Disorder IP
- 3 Patent Changes Can Boost Economic Growth, Profs Say
- Pot Co. Trulieve Seeks Quick Win In Background Check Row
- EPA Defends Its Revised Dicamba Policy After 9th Circ. Order
- Reed Smith Reps Perrigo's $50M Investment In CBD Supplier
- EPA Should Reexamine Fluoridated Water Risks, Judge Says
- Health Hires: Latham, Fox Rothschild, Saul Ewing
- Generic Cos. Ask Fed. Circ. To Deny Amarin's Vascepa Appeal
- Ex-Okla. GC Who Faked Email Threats Gets Suspension
- How To Handle Congressional Queries On COVID-19 Relief
- The Privilege Implications Of Using Online Collaboration Tools
- MDL Decisions Demonstrate The Need For Rule 702 Reform
- Biotech Co. Investors' FDA Convo Suit Survives Dismissal Bid
- J&J Says Imerys Ch. 11 Plan Lacks Info
- Calif. High Court Could Limit DA Enforcement Actions
- Pharmacies Want Out Of Opioid MDL 'Public Nuisance' Suits
- Boehringer Ingelheim Sued For €23M Over Diabetes Drug IP
- USTR Plans To Hold Mexico's Feet To Fire Under Trade Deal
- Lab Software Co. Says Worker's Visa Denial Hurts Virus Fight
- EPA Risk Assessment Director Stands By Fluoridated Water
- J&J CEO Falsely Painted As A Crook At Talc Trial, Court Told
- Worker Says She Was Fired Over Empty Medical Pot Package
- DC Circ. Rejects Trump's 'Far-Flung' Drug Pricing Rule
- Biotech Co. Asks 4th Circ. To Toss $22M Defamation Verdict
- Illumina Wins Bid To Block BGI Genomics' DNA Product Sales
- Royalty Pharma Raises $2.2B In Year's Largest IPO
- Post-Transaction Privilege Lessons From Del. M&A Opinion
- FDA Issues Warnings Over Unapproved Homeopathic Drugs
- Confronting Mental Distress In The Legal Profession
- Coronavirus Regulations: A State-By-State Week In Review
- Eagle Fights FDA's DC Circ. Bid To Undo Orphan Drug Win
- 'Pharma Bro' Shkreli Can't Delay Discovery In Antitrust Suit
- Banks May Need To Update Policies To Fight COVID-19 Fraud
- Native American Tribes Say Juul Targeted Them With Vapes
- How USPTO Examiner Type Affects Patents: Part 2
- Smart-Pill Maker Proteus Hits Ch. 11 After Cash Crunch
- Malaria Meds Don't Cure Virus, May Hinder Gilead Drug: FDA
- High Court Skips Challenge Over Doctrine Of Equivalents
- EPA Experts Say Fluoride Not Shown Toxic At Low Levels
- CBD Co. Execs Hit With Derivative Suit Over Patent Rejection
- USPTO To Speed Up Pandemic-Related TM Applications
- Inovio's '3-Hour' COVID Cure Claims Spark Derivative Suit
- Swedish Pharma Co. Targets US Partner In Arbitration
- Fla. Cannabis Co. Taps BigLaw Vet As Chief Legal Officer
- Centene Settles Hep C Class Suit
- COVID-19 Test Maker Sued Over '100% Accurate' Claim
- Litigation Finance Investments Are Not Risk-Free Loans
- $88M Cut From Requested $157.5M Atty Fee In Namenda Deal
- Minn. Senate Bill Floats Legalizing, Taxing Recreational Pot
- 4 Life Sciences Companies Launch IPOs Totaling $588M
- Pharmacies Can't Avoid Common Discovery In Opioid MDL
- High Court Won't Hear Drug Price-Fixing Discovery Dispute
- How Cos. Can Avoid Patent Venue Pitfalls Of Remote Work
- Ropes Helps Novavax Ink $200M PIPE Deal To Fight COVID-19
- High Court Takes Up Arbitration Carveout Question
- How White Privilege Helped Me Succeed In BigLaw
- EPA Defends Safety Of Fluoridated Drinking Water At Trial
- Cherokee Nation Fights Bid To Nix Opioid Bellwether
- 4 Takeaways As AbbVie Crushes 'Patent Thicket' Litigation
- Teva's $25M Consumer Settlement Gets Green Light
- Texas High Court Limits Forum Clauses To Signatories
- Safeway Escapes Whistleblower's Drug Price Suit
- Social Equity Lags Behind Progress In Pot Industry
- CVS-Only HIV Drugs Deny Meaningful Access, 9th Circ. Told
- Fed. Circ. OKs Medinol Patent Loss Despite Ax Of Laches
- Cannabis Bill Roundup: Colo. Fast-Tracks Social Equity Bill
- Stroock Nabs Greenberg Traurig Litigation Pro For NY Office
- Nature's Way Can't Dodge Revived Ginkgo Class Action
- 11th Circ. Won't Revive Female J&J Worker's Sex Bias Row
- Green Groups Ask 9th Circ. To Force Immediate Herbicide Ban
- Biotech Cos. Flood Public Markets With IPOs Over $900M
- Fed. Court No Place For Pot License Fight, Md. Agency Says
- Travelers Sues Qatar Airways Over $81M Cargo Damage
- $25M Penny Stock Scam Used COVID-19 Ruse, Feds Say
- Catalent Escapes Muslim Worker's Suit Over Prayer Breaks
- Coronavirus Q&A: Ropes & Gray's Tara Fisher
- Novartis Can't Duck Suit Over Cancer Drug Side Effects
- DSM Boosts Animal Gut Health Biz With €980M Erber Deal
- Robbins Geller Sues SEC For OvaScience Probe Docs
- Calif. Appeals Court Affirms Chemical's Listing As Carcinogen
- Coronavirus Q&A: Honigman's Life Sciences IP Leader
- CBD Co. Hits Back At Charlotte's Web In TM Row
- Congress Must Create More Private Rights Of Action
- Keys To A Thriving Biz Development Culture At Your Law Firm
- Davis Polk, Goodwin Steer Pharma Deal Worth Up To $2.1B
- Amazon, EBay Told To Stop Selling Unproven Virus Cleaners
- 1st Circ. Generic-Delay Ruling Isn't Popular With Lower Courts
- Philip Morris Taps Manatt Atty As General Counsel
- Hiscox Must Fund NY Drug Biz's Defense In Opioid Trial
- EPA Scientist Testifies Animal Studies Point To Fluoride Risks
- Cigna Jumps Into Pharmaceutical Generics Price-Fixing Fight
- Insys Manager Who Flipped On Bosses Avoids Prison Time
- 9th Circ. Rules Endologix Stock Suit 'Had No Basis In Logic'
- AGs Pile On Generics Cos. With 3rd Price-Fixing Complaint
- Fla. Pot Licensing Law Not Unconstitutional, Nursery Says
- COVID-19 Vaccine Developers Can Limit Liability From Trials
- Fed. Circ. Patent Rulings May Shift Use Of Motion To Dismiss
- How Video Mediation Can Help Us Serve Clients Better
- Buyer Says Muscle Supplements Contain Carcinogen
- Ex-GC Eyes Early Win Against CBD Co. Over Stocks, Benefits
- Calif. Backs Patent Atty's Whistleblower Suit Against Allergan
- Kessler Topaz Named Lead Counsel In Becton Securities Suit
- Mental Health Efforts Will Support Diversity In Legal Industry
- Feds Charge Biotech Exec, Investor In COVID-19 Test Scam
- Fluoride In Water Is 'Endangering' Children's IQs, Judge Told
- GAO Says Outdated Inventory System Hurt VA Virus Response
- Merck Can't Wipe Out Microspherix's PTAB Win
- Insulin Wholesalers Want Consumers To Get Out Of Their Way
- FTC, Impax Spar At 5th Circ. Over Opana ER Deal
- Foley Hoag Hires Ex-Norton Rose Patent Partner In NY
- Zantac Users Push To Consolidate Calif. Cancer Suits
- PetIQ Merger Fight Faces Skeptical Judge At 9th Circ.
- Coronavirus Regulations: A State-By-State Week In Review
- State Of Enviro Enforcement After Trump's Deregulatory Order
- Feds Tell High Court To Reject Arthrex Appeal On IPR
- UK Clears Elanco's $135M Divestiture For Bayer Deal
- Servier Urges Justices To Play By EU Pay-For-Delay Ruling
- Patent Specification Has Become Vital For Nonabstract Claims
- Medical Packager Says Union Staff Can't Sue In Privacy Fight
- Law Profs Urge Fed. Circ. To Narrow Assignor Estoppel Rule
- Bull Semen Co. Boosts Win Against Rival To $11M In IP Row
- Bayer, Merck Beat Dr. Scholl's Buyer's Leg Amputation Suit
- SEC Cuts Accountant Slack For Self-Reporting Insider Trading
- Judge Says Cert. Unlikely For Parent ADHD Med Buyers
- Texas Hemp Group Asks State To Allow Sale Of Smokables
- Jailed Biotech Inside Trader Gets 5-Year Ban In SEC Case
- Bankruptcy Court Can't Touch Pot Patent, Trustee Says
- General Dynamics Unit Must Face $13M Contract Breach Suit
- EPA Cancels Approval Of Dicamba Pesticide
- 3M Sues Amazon Seller Over Fake N95 Masks
- FTC, States Fight Shkreli Bid To Delay Antitrust Suit Discovery
- AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'
- New Ruling May Aid Syndicated Loan Market Amid Pandemic
- Supplements Co. Hit With Suit Over Muscle-Building Claims
- Royalty Pharma Leads Life Sci Trio Set To Raise $2.2B In IPOs
- EU Approves Elanco's $7.6B Bayer Animal Biz Buy
- What State Laws On COVID-19 Liability Protection Look Like
- Pandemic Collaborations Pose Risk Of Future Patent Disputes
- COVID-19 Product Liability And The 'Innocent Seller'
- Workers Insist Yale's Wellness Program Not Really 'Voluntary'
- Civility Could Be Litigators' New Normal Even Post-Pandemic
- Talks Underway To End Cocrystal Pharma Stock-Drop Suit
- £220M NHS Suit Over Drug Patent Heads To Supreme Court
- CEO's Junk-Fax Win Can't Help Med Supply Co., 7th Circ. Says
- Takeda, Eli Lilly Lose High Court Bid Over Actos RICO Claims
- 7th Circ. Sanctions Amazon Seller Over Doomed Appeal
- 3 Firms Assist As Brookfield Injects $260M Into Superior Plus
- Teva Invalidates Opiant Patents In Narcan Suit
- Calif. Trial To Decide Risk Of Fluoride In Drinking Water
- 3M Says Ex-Marine Faked Bill Gates Ties In Massive N95 Scam
- Trio Of Life Science Cos. Raise Combined $660M In IPOs
- Coronavirus Q&A: King & Spalding's Health Team Leader
- Crackdown On Chinese Cos. Could Be A Double-Edged Sword
- FCA Ruling Shows Importance Of Relator As Original Source
- The Week In Bankruptcy: Eyes On The New Normal
- Investors Accuse Curaleaf Of Downplaying Stock Drop Claims
- Chinese Investors Urge 9th Circ. To Uphold Discovery Order
- Law Firms Must Beware Risks In Nontraditional Financing
- 'The Government Said I Could' As A Defense During COVID-19
- ED Treatment Maker Nears Deal With Rival In Contract Spat
- Fed. Circ. Won't Say If Premature Alice Ax Bars Invalidity Bid
- COVID-19 IP Catch-Up: Publishers, Vodka Co. Head To Court
- Crucial COVID-19 Drug Patent Considerations For Universities
- Proskauer Assists As Atlas Venture Wraps Up $400M Fund
- Health Hires: Epstein Becker, Clyde & Co., Prevail
- CardioNet Tries To Save Patent By Citing IP Win In Other Case
- 4 Highlights As CDC Chief Eyes Perilous Path For Pandemic
- Conn. Health Care Worker Says She Was Axed For Medical Pot
- Fed. Circ. Says It Can't Award Atty Fees Tied To PTAB Cases
- Drug Firm Hurt By Coronavirus Gets Ch. 11 Plan OK'd
- Invisalign Maker Says Judge Botched Antitrust Analysis
- Iowa Legislators Pass Bill Limiting Medical Marijuana THC
- EU High Court Told To Uphold €94M Pay-For-Delay Fine
- Market Recovery Gains Steam With ZoomInfo's $935M IPO
- Coronavirus Litigation: The Week In Review
- Calif. Pot Regulators Limit Public Licensee Info After Looting
- Inovio Sues Supplier For Holding COVID-19 Vaccine 'Hostage'
- Chancery Advances Investors' $1.2B Drug Control Suit
- Wilson Sonsini-Led Pharma Co. Scores $85M In Funding
- 2 Tested Alternatives To Unavoidable Court Delays
- Minn. Ruling Represents Sensible Stance On Legal Finance
- 2nd Circ. Sends Amazon Customer's Drug Row To Arbitration
- Beware Fraud And Abuse Pitfalls In Precision Medicine
- Ill. High Court Boots Out-Of-Staters From Bayer Device Suit
- UK Pharma Exec Barred After Admitting To Drug Supply Plot
- No Cert. For End-Payors In Niaspan Pay-For-Delay MDL
- 9th Circ. Nixes EPA Approval Of Dicamba Herbicides
- SEC Sues Fla. Firm Pushing Investments In COVID-19 Cure
- Fed. Circ. Judge Probes 'Possible Mischief' In Biosimilar Law
- Opioid MDL Judge Orders More Briefing On $3B Atty Fees
- Gilead Can't Shake New HIV Antitrust Complaint, Court Told
- 2nd Circ. Sends FCA Discount Case For 'Original Source' Look
- Pharmacy Chain Says It Can Rep Class If Lead Is DQ'd
- Portola Investor Cries Foul Over Tender Offer Math
- And Now A Word From The Panel: Pandemic MDLs
- Best Practices For A Paperless Law Practice
- Fed. Circ. OKs Pharma Delivery Co.'s Mixed $24M Breach Win
- Purdue's Ch. 11 Claim Deadline Bumped 30 Days For Virus
- Fla. Judge Recuses Himself In CR Bard Vein Filter Suit
- How Licensing Affects Patent Damages Apportionment: Part 3
- Mylan Gets OK To Sell Generic Insomnia Drug During IP Fight
- Goodwin-Led Pliant Therapeutics Shares Pop After $144M IPO
- Cannabis Lobbies Urge 9th Circ. To Dump Pot Biz Tax Law
- 4 Highlights As Senators Eye FDA Actions On COVID-19
- 1st Circ. Says Novo Nordisk Can't Block Ex-Worker's New Job
- Investors Fight Cannabis Co.'s Bid To Nix Stock-Drop Suit
- Monsanto Says $78M Roundup Verdict Barred By Federal Law
- Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License
- PhRMA Says Fed. Circ. Botched Patent Term Extension Ruling
- Coronavirus Regulations: A State-By-State Week In Review
- 5 Ways A Special IG Can Combat Crisis Relief Fraud
- Sanofi Boots Some Plaintiffs From Chemo Hair Loss MDL
- Lawyers Must Address Racial Injustice With Radical Candor
- How NJ Talc Case May Shift NY Courts On Expert Testimony
- Calif. Dental Board Says SmileDirect Claims Still Not Straight
- Acadia Can't Slip Investor Suit Over Parkinson's Drug Deaths
- ZoomInfo, Pliant Therapeutics Bulk Up IPOs Before Pricing
- Pet Supply Co. Trims $12.6M Award In Product Patent Suit
- Teva Can't Escape Infringement Claim In Inhaler Patent Suit
- Esperion Investor Class Wins Cert. In Cholesterol Drug Row
- Drug Co. Wants 'Free Pass' For Shady Opioid Sales, DOJ Says
- Imprisoned NECC Pharmacist Can't Get COVID-19 Release
- Rhode Island High Court Upholds Medical Pot Patient's Firing
- EPA Finalizes Ethylene Oxide Reduction To Lower Cancer Risk
- Generics' 2nd Challenge To Acne Drug IP Succeeds At PTAB
- Asbestos Battles Show One Possible Fate For J&J After Talc
- Contractors Can't Escape Insurer's $1.4M Water Damage Suit
- Bausch Says Investors' Price-Gouging Claims Came Too Late
- Seed Co. Gets Award For Stolen Trade Secret Upped To $9M
- COVID-19 Securities Catch-Up: SEC Enforcement
- 3 Firms Help Two Biotechs Term IPOs Worth $205M
- How Lawyers Can Network Better, Virtually And In Person
- Practical Tips For Presenting Your Case To Litigation Funders
- Compliance Tips For Development Bank COVID-19 Projects
- Immunomedics Must Face Suit Over Drug Presentation Claims
- Bayer Slams Pet Med Co.'s Bid To Serve Docs Via Email
- Quinn Emanuel Nabs Ex-Williams & Connolly Patent Pro In DC
- Lieff Cabraser Snags $40M Fees From Sandoz, Momenta Deal